announced today that five oral presentations including a symposium, and two poster presentations, highlighting the latest data on its Alzheimer's disease / dementia pipeline including anti-amyloid beta (Abeta) protofibril antibody BAN2401, oral beta secretase
cleaving enzyme (BACE) inhibitor elenbecestat, anti-Abeta antibody aducanumab, and dual orexin receptor antagonist lemborexant, will be given at the 11th Clinical Trials on Alzheimer's Disease (CTAD) conference taking place in Barcelona, Spain, from October 24 to 27.
- Indianapolis, Indiana-based global pharmaceuticals specialist Eli Lilly and Company (NYSE: LLY) and Wilmington, Delaware-based prescription medicines specialist AstraZeneca-US are discontinuing the global Phase 3 clinical trials of lanabecestat, an oral beta secretase
cleaving enzyme inhibitor, for the treatment of Alzheimer's disease, the companies said.
United Kingdom-based AstraZeneca and United States-based Eli Lilly have terminated global phase three clinical trials of Alzheimer's disease treatment, lanabecestat, which is an oral beta secretase
cleaving enzyme inhibitor, it was reported yesterday.
Eli Lilly (LLY) and AstraZeneca (AZN) are discontinuing the global Phase 3 clinical trials of lanabecestat, an oral beta secretase
cleaving enzyme, or BACE, inhibitor, for the treatment of Alzheimer's disease.
and AstraZeneca have entered an agreement to co-develop and commercialize AZD3293, an oral beta secretase
cleaving enzyme (BACE) inhibitor in development as a potential treatment for Alzheimer's disease (AD).
Both the AstraZeneca and Merck medicines work by blocking an enzyme called beta secretase
that is involved in production of beta-amyloid, a protein that creates brain plaques considered a major cause of Alzheimer's disease.
"Recent research has revealed mutations at what is called the 'beta secretase
site'--the point where BACE1 cuts the amyloid precursor," says Dr.
Pratico said that their research has shown that 12/15-Lipoxygenase controls Beta secretase
(BACE-1), an enzyme that is key to the development of amyloid plaques in Alzheimer's patients.
"By working too much, it sends the wrong message to the Beta secretase
, which in turn starts to produce more amyloid Beta.
, a protease that cleaves amyloid precursor protein and results in toxic [beta]-amyloid peptides, may also be upregulated by inflammatory mediators.
"There is compelling evidence that sAPPbeta, the ectodomain of amyloid precursor protein (APP) shed through beta secretase
cleavage, is an important component in the pathogenesis of AD," said Joe Bertelsen, neuroscience product manager, Covance.